BCM
PRTK

BlueCrest Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

BlueCrest Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-19,361
Closed -$605K – 956
2015
Q1 		$605K Buy
+19,361
New +$556K 0.03% 435

Other funds holding PRTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlueCrest Capital Management's PRTK Position: Q2 2015 in Review

BlueCrest Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2015, closing a stake of 19,361 shares — an estimated $605K sold.

BlueCrest Capital Management first reported a position in PRTK in Q1 2015 and held it in 1 quarter. The position peaked at $605K in Q1 2015. 68 funds tracked by Wall St. Rank hold PRTK as of Q2 2015.

  • BlueCrest Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • BlueCrest Capital Management sold 19,361 Paratek Pharmaceuticals, Inc. shares in Q2 2015, an estimated $605K.
  • BlueCrest Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • BlueCrest Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $605K in Q1 2015.
  • 68 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2015.

Based on BlueCrest Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.